header logo image


Page 681«..1020..680681682683..690700..»

Eminent Ophthalmologist VK Raju honored by Egyptian Ophthalmology Society – The Indian Panorama

March 1st, 2020 9:42 am

Founder-President of Eye Foundation of America Dr. VK Raju was honored by the Egyptian Ophthalmology Society with a medal for his contribution in the field of prevention of blindness among children worldwide

CAIRO (TIP): Dr. VK Raju, an eminent ophthalmologist based in Morgan Town, West Virginia, USA was invited to Cairo by the Egyptian Ophthalmology Society to speak on childhood blindness. He lectured on difficult cataract surgery, prevention of blindness in premature children. The condition is called ROP (retinopathy of prematurity). If premature babies are given too much oxygen, it can be harmful. It leads to bleeding in the eye and causes permanent blindness. The good news is it can be prevented by laser treatment. Early recognition is the key.

Dr. Raju who is Founder and President of the Eye Foundation of America is a passionate crusader for prevention of avoidable childhood blindness. His passion takes him to many parts of the world, particularly to his country of origin India where he has set up a hospital and eye institute in Rajahmundry, Andhra Pradesh. At the Goutami Eye Institute, Rajahmundry, a dedicated staff serves a large community, particularly rural.

Dr. VK Raju is internationally recognized and has been honored by many organizations. Only this January, Rotary Club of Calcutta, the oldest Rotary club, at their centenary celebrations, honored Dr. Raju for his tremendous contribution.

Visit link:
Eminent Ophthalmologist VK Raju honored by Egyptian Ophthalmology Society - The Indian Panorama

Read More...

Gene therapy shows promise in tackling common cause of childhood blindness – Mirage News

March 1st, 2020 9:42 am

The results of a first-in-human clinical trial of gene therapy to treat a common cause of genetic blindness have shown partial reversal of sight loss in some patients.

X-linked retinitis pigmentosa, caused by mutations in RPGR gene, is the most common cause of blindness in young people. The inherited mutations lead to degeneration of light sensitive cells (photoreceptors) beginning in early childhood leading to severe sight loss.

Until now there has been no treatment for this disease. Gene therapy using viral vectors to deliver a healthy copy of a mutated gene into affected cells aims to slow down the degeneration and preserve visual function.

However, the RPGR gene has an unusual genetic code which makes it unstable to work with in the laboratory and until now difficult to translate into human trials.

Scientists at the University of Oxford reprogrammed the genetic code of the RPGR gene to make it more stable, providing the basis for this first-in-human retinal gene therapy.

The international trial, led by Professor Robert MacLaren, was sponsored by Biogen Inc., with support from the NIHR Oxford Biomedical Research Centre.

Eighteen patients in total were treated with increasing doses of the vector carrying an RPGR gene in which the DNA had been altered, but in a manner that still allowed correct production of the missing protein.

Other trial sites included the Manchester Royal Eye Infirmary and the Bascom Palmer Eye Institute in Miami.

The research teams findings are published in the journal Nature Medicine.

Professor MacLaren, Consultant Ophthalmologist at the Oxford Eye Hospital, commented: We are delighted with the early results of this clinical trial for a degenerative eye disease. It is becoming more apparent to us that novel genetic therapies, when working, lead to a clear improvement in neuronal function, which holds great hope for a variety of other degenerative conditions that have a genetic basis.

Once again, we should take note that this highly successful international gene therapy clinical trial originated in the NHS by applying science that was previously developed in a project funded in the UK by the Medical Research Council.

The early results from the study showed that the treatment was safe and six patients who received mid doses of the vector had unexpected improvements in their peripheral vision beginning as early as one month after the treatment.

One of Professor MacLarens patients, Kurtis Lonie, said: When my mum spotted the trial in an RNIB newsletter I felt so hopeful about what I was reading. At this stage in my life I was struggling deeply with what I thought my life would become. The speed of my conditions degeneration was unknown so I had no choice but to apply and do whatever I could to hopefully help others in the future, as well as myself.

After undergoing tests and screening, Kurtis was given the choice of which eye he wanted to be treated, and he opted for the one with worse vision.

About a month after the treatment my vision was beginning to return in the treated eye. The sharpness and depth of colours I was slowly beginning to see were so clear and attractive. My visual field exploded and I could see so much more at once than ever before in that eye. Before long, the eye was undoubtedly better than the untreated eye.

The results have been nothing short of astonishing and life changing for me, I really hope this trial is approved and they can treat what once was my better eye.

This improvement in peripheral vision experienced by some patients is believed to relate to regeneration of outer retinal structures following successful gene therapy and has implications for the development of similar gene-based treatments for many other retinal degenerations.

Nightstar Therapeutics was a University of Oxford spinout company founded in 2014 and listed on NASDAQ in 2017. The RPGR gene therapy developed in Oxford was licenced to Nightstar in order to set up the international clinical trial.

In 2018 Nightstar Therapeutics was acquired by the large US biotech company Biogen, in what was one of the biggest buyouts of a British biotechnology company to date.

The funding raised combined with the successful start of the clinical trial has highlighted the huge potential for academic collaborations between UK universities, the Department of Health and the global biotechnology sector. This has been a key long term strategic aim of the NHS funding directed through the National Institute for Health care Research (NIHR).

Link:
Gene therapy shows promise in tackling common cause of childhood blindness - Mirage News

Read More...

Katsina Has 25,000 Blind Persons, Says Foundation – THISDAY Newspapers

March 1st, 2020 9:42 am

By Francis Sardauna

A United Arab Emirates (UAE) based non-governmental organiSation, Noor Dubai Foundation on Friday revealed that Katsina State has 25,000 blind persons with only four ophthalmologists spearheading its eye care centre.

Pained by the menace, the charitable organisation in collaboration with the state government, said it had inaugurated a four-year integrated and sustainable eye care programme to improve quality of life and socioeconomic status of the affected persons.

The representative of the foundation, Dr. Rabiu Mansour, who disclosed this to journalists in Katsina while speaking on the achievements of the programme, said six million Katsina citizens were expected to benefit from the programme within the period under review.

He explained that the foundation, which commenced the programme in October 2019, had so far conducted 1,039 successful cataract surgeries and eye screening for 5,238 patients in Katsina, Daura and Funtua general hospitals within four months.

He reiterated that 2,313 visually impaired persons had been treated with either medications or eye glasses, six ophthalmologists and optometrists and one optician had been employed to boost efficient service delivery.

Katsina state has over 25,000 blind people and another 100,000 people with some visual loss, but there are only four ophthalmologists to cater for this population. Currently only about 10 to15 per cent of eye care services are being covered in the state.

In line with Noor Dubai Foundations new strategic plan, it set up a four- year (2019-2023) integrated and sustainable comprehensive eye care programme in partnership with Katsina state government. In addition, a Nigerian office of the Noor Dubai Foundation have been set up in Katsina.

The programme is aim at improving quality of life and socioeconomic status of people of the state through improved access to quality eye care. It will cost about $2 million with the Katsina state government contributing additional 20 per cent in kind.

We intend to conduct cataract surgeries for 12,000 people to restore their sights and 37,000 people are to be screened and treated for eye diseases. While 320,000 school children will also undergo eye screening and treatment. And 1,000 people with permanent visual loss will be rehabilitated, he added.

In his remarks, the State Commissioner for Health, Yakubu Nuhu Danji, said about 4,000 visually impaired people were consulted and 2,000 have been treated by the foundation.

While admitting that the state has 25,000 people suffering from blindness, the commissioner said the alliance between state government and the foundation would eradicate the impediment.

He said: As you are all aware, Katsina state has 25,000 people suffering from blindness and right now we only have four ophthalmologists manning the eye centre we have.

Danja said the state government had inaugurated an awareness committee to educate the residents, particularly rural dwellers on the need to patronise the eye care centres to prevent them from impairment.

Meanwhile, the foundation, established by the Vice President, Prime Minister of UAE and the ruler of Dubai, Sheikh Mohammed bin Rashid Al-Maktoum in 2010 focused on prevention of blindness and visual impairment globally.

Over 27 million people in 18 countries across Africa and Asia were said to have benefited from the free treatment and prevention programmes conducted by the Foundation.

Go here to see the original:
Katsina Has 25,000 Blind Persons, Says Foundation - THISDAY Newspapers

Read More...

World Rare Disease Day: Are they more common than you think? – Outlook India

March 1st, 2020 9:42 am

World Rare Disease Day: Are they more common than you think?

New Delhi, Feb 29 (IANSlife) World Rare Disease Day is observed every year on the last day of February.

A Rare Disease is also known as Orphan Disease and is said to affect a small percentage of the population. It presents a countless number of challenges for patients and their family members, including the time it takes to obtain a correct diagnosis.

Although cancer and heart disease get plenty of media attention, the impact and reach of rare diseases vary significantly. One of the rare diseases may affect only a handful of patients, while another disease could affect many. At times, Rare Diseases are difficult to diagnose because of its nonspecific symptoms and because they''re so unusual.

It is said that 1 in 20 Indians is affected by a Rare Disease. According to Indian Society for Clinical Research (ISCR). 70 million in India and 350 million people around the world suffer from rare diseases.

There are more than 7,000 distinct types of Rare and Genetic diseases and it has impacted more people than Cancer and AIDS combined and most of which are progressive, life-threatening, and chronically debilitating conditions and 80 percent of these rare diseases have a genetic origin.

Dr. Mayuri.K.S., Consultant Microbiologist and Infection Control Officer, SPARSH Hospital, Bengaluru shares few types of rare diseases:

Acanthamoeba keratitis

Acanthamoeba keratitis is a vision-threatening rare disease which causes parasitic infection and can be seen most often in contact lens wearers. It is found ubiquitously in soil and water and can cause infections of the skin, eyes, and central nervous system.

This infection of the cornea is difficult to treat with conventional medications. It may lead to permanent visual impairment and blindness in some cases because of damage to the clear portion of the front of the eye called the cornea or through damage to other structures important to one''s vision.

Creutzfeldt-Jakob disease (CJD)

Creutzfeldt-Jakob disease is also known as Classic Creutzfeldt-Jakob disease. CJD is a fatal degenerative brain disorder which is believed to be caused by a protein known as prions. The early symptoms include visual disturbances, memory problems, behavioural changes and also poor coordination.

The later symptoms include weakness, involuntary movements, blindness, dementia and coma. About 70 percent of people die within a year of diagnosis as there is no specific treatment for CJD.

Cysticercosis

Cysticercosis is a rare infectious disease. It is a tissue infection which is caused by the tapeworm present in the pork. It is known to cause neurocysticercosis which affects the brain and can cause neurological symptoms. Individuals suffering from this rare disease may have few or no symptoms for years.

Cysticercosis is usually acquired by eating contaminated food. One of the major sources is said to be uncooked vegetables. Drinking water contaminated by tapeworm eggs from human feces is also one of the main reasons to cause the infection.

Mucormycosis

Mucormycosis is caused by fungi in the order Mucorales. And they are generally the species in the Mucor, Rhizopus, Absidia and Cunninghamella. The disease is often characterized by hyphae growing in and around blood vessels and can be potentially life-threatening in diabetic or severely immune-compromised individuals.

Mucormycosis and zygomycosis are sometimes used interchangeably. It frequently infects the sinuses and the brain. While infection of the oral cavity or brain is the most common form of mucormycosis and it enters the body through a cut in the skin. The fungus can also infect other body areas such as the gastrointestinal tract, other organ systems and in rare cases, the maxilla may be affected by mucormycosis.

Fungal infections are usually prevented by the rich blood vessel supply of maxillofacial areas. Although more virulent fungi responsible for mucormycosis can often overcome this difficulty.

Naegleriasis

It is also known as PAM - Primary Amoebic Meningoencephalitis. This rare disease is an almost invariably fatal infection of the brain by the free-living unicellular eukaryote Naegleria fowleri. Symptoms are meningitis which includes headache, fever, nausea, vomiting, a stiff neck, confusion, hallucinations and seizures. Symptoms progress rapidly over five days and death usually results within one-to-two weeks of symptoms.

Nocardiosis

Nocardiosis is an infectious disease affecting either systemic nocardiosis which is the whole body or pulmonary nocardiosis which are the human lungs. It is caused due to an infection by a bacterium of the genus Nocardia, most commonly Nocardia asteroides or Nocardia brasiliensis. It is most commonly seen in adult males, especially those with a weak immune system.

Patients with brain Nocardia infection, mortality exceeds 80%, in other forms, mortality is 50%, even with appropriate therapy. It is one of several conditions that have been called "the great imitator" and Cutaneous nocardiosis commonly occurs in immunocompetent hosts.

Rat-bite fever

It is an acute, febrile human illness caused by bacteria transmitted by rodents, in most cases, which is passed from rodent to humans by the rodent''s urine or mucous secretions. Alternative names for this rare disease include streptobacillary fever, streptobacillosis, spirillary fever, bogger, and epidemic arthritic erythema. It is spread by infected rodents and can be caused by two specific types of bacteria.

In some of the cases are patients were diagnosed after they were exposed to the urine or bodily secretions of an infected animal. These secretions can come from the various body parts like mouth, nose or eyes of the rodent and majority of cases are due to the animal''s bite. It is also said to be transmitted through food or water contaminated with rat feces or urine.

Other animals that can be infected with this disease are household pets, weasels, gerbils and squirrels. It is important to quickly wash and cleanse the wound area thoroughly with an antiseptic solution to reduce the risk if a person is bitten by a rodent.

Cat-scratch disease (CSD)

It is caused due to scratching or biting of a cat. Typically include a non-painful bump or blister at the site of injury caused due to scratch or bite. Within 3-14 days following infection and the individual may feel tired, have a fever and headache.

Cat scratch disease is caused by the bacterium Bartonella henselae spread by the cat''s saliva. Young cats pose a greater risk than older cats. Diagnosis is generally based on symptoms but confirmed through blood tests.

The primary treatment is supportive. Recovery occurs within four months but can require a year. About 1 in 10,000 people are affected and it is found to be more common in children. These diseases may seem to be rare, but there is a significant figure that highlights just how many people are living with it but that gets a little attention due to their singularity. The challenges they face are common to millions of people across the world.

There is much work to be done to spread the awareness of rare diseases and also to improve the diagnosis and treatment of rare diseases. Only less than 5 percent of the 7000 rare diseases have approved therapies. On average, the rare disease patient waits about five years from symptom onset to accurate diagnosis.

In order to tackle the challenges that people living with a rare disease and their families face every day, awareness campaigns should focus on bridging all the gaps in the coordination between medical, social and support services.

--IANS

lh/adr/sj/

Disclaimer :- This story has not been edited by Outlook staff and is auto-generated from news agency feeds. Source: IANS

Continue reading here:
World Rare Disease Day: Are they more common than you think? - Outlook India

Read More...

Cynthia Taylor: Speaker will address the question Can we all get along? – The Augusta Chronicle

March 1st, 2020 9:42 am

A mutually hurting stalemate. That seems to be a good description of where we are as a country and its tearing at our souls. This doesnt just apply to our political divisions, which seem insurmountable, but also to the racial divide in our country.

Nearly 30 years ago, riots broke out in Los Angeles over the acquittal of police officers who had been accused of savagely beating Rodney King. At the height of the riots, an anguished King appeared on television asking the haunting question, Can we all get along? That question is written on his gravestone.

Apparently, the answer seems to be, No, we cant get along. Or can we?

The Rev. Gary Mason, a Methodist minister from Northern Ireland, has spent his life working on how to answer the question, Can we all get along? The divisions in that country were as deep or deeper than anything were currently experiencing in America. And yet, Mason was one of those who became involved in the peace process in Northern Ireland that has led to reconciliation. He was recognized by Queen Elizabeth for his work in the peace process.

At the Last Supper, Jesus prayed that we all may be one. But becoming one doesnt mean its easy nor does it mean we all end up thinking alike. Like those in Northern Ireland, we dont know how to put down our weapons. Here our weapons are words and actions that demonize others, making them seem less than children of God, made in the image of God.

Such violence has led to what Mason calls the mutually hurting stalemate. Those of us who follow Jesus call him the Prince of Peace, but we dont always live into being peacemakers ourselves. We dont know how to disagree well without being disagreeable. We dont know how to have the hard conversations with those who differ from ourselves.

We have just begun the season of Lent and, in my tradition, it began this past week with Ash Wednesday a service of repentance and reconciliation with God and others.

In part of the service called The Litany of Penitence, we ask God to accept our repentance for the wrongs we have done; for our blindness to human need and suffering for all false judgments and for our prejudice and contempt toward those who differ from us.

True repentance is not just acknowledging all the ways we have fallen short but living into a new way of being, a new way of life.

Gary Masons life work is teaching how to live into a new way of being and doing the hard, hard work of reconciliation. Its not wrapping ourselves in a cocoon of naivety that peacemaking is easy. Its not. But, sweet Lord, is it ever necessary, now more than ever.

Mason will be in Augusta for a series of events on Reconciliation: Healing the Hurt. These will be held at Church of the Holy Comforter, 473 Furys Ferry Road, Martinez. The first is a Community Forum on Saturday, March 7 from 6-8 p.m. Then he will be teaching and preaching Sunday, March 8, beginning at 9:15 a.m. in the Rectors Forum and worship at 10:30 a.m. All events are free and open to the public.

After his work in Northern Ireland, Mason started Rethinking Conflict, an institute devoted to social justice, conflict transformation, peace building and addressing religious fundamentalism. He is an adjunct professor at Candler School of Theology and the Kennedy Institute for Conflict Intervention in Maynooth University, Ireland.

Can we all get along? How will you answer that question?

The Rev. Cynthia Taylor is the pastor of the Church of the Holy Comforter in Martinez.

Visit link:
Cynthia Taylor: Speaker will address the question Can we all get along? - The Augusta Chronicle

Read More...

Microsoft Invests In A New AI For Health Initiative – Forbes

March 1st, 2020 9:42 am

As one of the richest people in the world, Bill Gates is known for contributing to global health through the Gates Foundation. As his biggest legacy, Microsoft is also moving in the same direction. The company is actively involved in helping the worlds population overcome some of the most challenging health problems and concerns.

Microsoft recently announced a new healthcare initiative known as AI for Health, a program worth over 40 million dollars. AI for Health evolved out of the AI for Good Program, which offers general aid to the less fortunate around the world.

The new initiative will primarily focus on health-related problems and the integration of AI and tech solutions. The main goal behind AI for Health is to directly research the impact of AI in the medical field, as well as develop algorithms for automatic detection of diseases and other medical operations. Besides building new solutions, the program will also work toward making these technologies more available worldwide.

AI for Health is a philanthropic initiative that complements our broader work in Microsoft Healthcare. We will support specific nonprofits and academic collaboration with Microsofts leading data scientists, access to best-in-class AI tools and cloud computing, and select cash grants, wrote Microsofts John Kahan in the official announcement of the new initiative.

How AI Can Aid the Healthcare Industry

Even to this day, underdeveloped countries are very far from being able to afford and implement AI technology in medical treatments. There is no doubt that modern healthcare solutions are distributed unevenly, leaving the population of some countries to die of diseases that dont even exist in modern countries anymore.

Even though AI cannot directly aid in distributing healthcare evenly, research in this field can help provide more affordable solutions. For example, AI can be used to build reliable screening systems for disease detection, more specifically for diabetic retinopathy which leads to blindness if not treated in time. AI-based systems would serve as cheaper and easier diagnostic processes for patients around the world.

Microsofts program aims to encourage the best experts in the field to actively help engineer and deploy such solutions. There is no doubt that the companys monetary investment is going to help push this project to the right direction. The company has already made several important partnerships with parties that can benefit from this research.

The AI-oriented research will look for solutions for various diseases and issues including tuberculosis, maternal mortality, and even cancer. It is also important to mention that Microsoft has decided that the new initiative wont be open for public organizations. Instead, it will be working directly with the privately chosen non profits and research organizations.

Go here to read the rest:
Microsoft Invests In A New AI For Health Initiative - Forbes

Read More...

3 High-Risk, High-Reward Stocks That Have Massive Upside Potential – The Motley Fool

March 1st, 2020 9:42 am

There are a lot of promising stocks out there for investors to choose from. However, if you're looking for companies with the most growth potential, the world of small-cap stocks is one of the best places to look.

In particular, biotech stocks are very well known for having tremendous upside potential. New drug candidates can easily bring in billions in revenue for companies, should they prove to be a success. However, many of these stocks are quite risky investments, especially since a good number are barely reporting any revenue figures whatsoever.

If you're comfortable with these types of investments, here are three high-risk, high-reward stocks that you should keep your eye out for in the future.

Image source: Getty Images.

Gene editing is an incredibly promising market that many biotech investors are paying close attention to. There are plenty of genetic disorders out there that might not be treatable with today's technology, but could be cured with the use of gene editing treatments in the future. Editas Medicine (NASDAQ:EDIT) is one company in this space that boasts a number of promising drug candidates, and it also has an impressive patent portfolio.

Editas's flagship drug candidate is EDIT-101, a treatment for a rare form of blindness in children called leber congenital amaurosis (LCA), which leads to a loss of eyesight as the retina fails to function properly. Although LCA is rare, affecting only 2 to 3 newborns per 100,000, the good news for Editas is that not many companies out there are trying to treat this condition.

Currently, the only other treatment for LCA is Luxturna, a drug developed by Spark Therapeutics. Besides the massive $850,000 price tag (or $425,000 for just one eye), Luxturna only works for a very specific variant of LCA, with most of the patient population not qualifying for the treatment.

EDIT-101, on the other hand, would be available for all LCA patients. Assuming EDIT-101 is priced somewhere near Luxturna's price point, the company would need to treat just 1,300 LCA patients annually for EDIT-101 to make over $1 billion in revenue. Considering that Editas made only $3.8 million in its recent third-quarter 2019 results, it's easy to see how positive results from this one drug alone could catapult the company's stock to new highs.

EDIT-101 is currently undergoing early clinical trials and likely won't be available for a couple of years at the earliest, if not longer. There is one other small-cap biotech stock,ProQR Therapeutics, working on a possible LCA treatment,but it's doing so without any backing from other, larger pharmaceutical giants.

In comparison, Editas has partnered with Allerganto help commercialize EDIT-101 should it become a success. Having a big partner such as Allergan with strong connections in the industry is a big advantage for any small-cap biotech stock looking to market its candidates.

Back in early January, I argued that Puma Biotechnology (NASDAQ:PBYI) was far from a good investment. By the end of 2019, the stock had lost around95% of its market capin comparison to where it was just a couple years before. Coupled with uncertainties regarding the appeal of its main drug, Puma's future looked very uncertain.

However, the stock has seen a surprising comeback over the past couple of months, surging by about 22%. The weird thing is that there's not much in the way of news to justify this rise. Puma's recent fourth-quarter results were pretty bad, with revenue down 11.5% to $62.9 million from last year, although this still slightly beat out analyst expectations.

Image source: Getty Images.

Puma's main treatment is its cancer drug Nerlynx, which is given to adults who have early stage HER2-positive breast cancer (a form of the disease that tests positive for a protein called human epidermal growth factor receptor 2, or HER2, which promotes the growth of cancer cells). The problem is that Nerlynx causes severe diarrhea as a side effect, which has led to a startlingly high discontinuation rate among patients.

While the company is making efforts to tackle this problem, such as providing vouchers for anti-diarrheal medications, it's still uncertain whether Nerlynx sales will recover.

The silver lining behind all this is that Puma is incredibly cheap, with the stock currently trading at a measly 1.9 price-to-sales ratio. While I don't think there's much hope for Nerlynx as a blockbuster cancer drug, there's a solid chance that Puma could become a buyout target for another, larger biotech company, considering how cheap its stock is. Should this happen, shareholders would see a significant surge in Puma's stock price following the news.

If you want to buy in anticipation of this, however, it might be best to wait for the stock to dip back down in value again. Considering that this recent surge doesn't seem backed by anything substantial in terms of news or catalysts, it wouldn't be surprising for the stock to tumble down once more. Long-term, however, Puma has a good shot at becoming an acquisition target, and as such, has a fair bit of upside potential in 2020.

Xenon Pharmaceuticals (NASDAQ:XENE) is a small-cap biotech stock that, by the end of the year, could easily have three late-stage drug candidates in its pipeline.

Its flagship drug, XEN496, is one of Xenon's promising epilepsy treatments, and is on the cusp of entering phase 3 trials.

XEN1101 is another epilepsy candidate that's currently in phase 2 trials, while XEN007 is a candidate also in phase 2 trials and is meant as a treatment for orphan neurological indications, which includes symptoms such as migraines, vertigo, and certain types of epilepsy.

Xenon has also grabbed the attention of a number of pharmaceutical giants interested in its drug candidates. Merckand Rocheare the two standouts, while Flexion Therapeuticsand Neurocrine Bioscienceshave also signed strategic partnerships with Xenon.

These agreements have helped finance Xenon's clinical development, with the company receiving $50 million in cash and equity from Neurocrine back in December.

Another one of Xenon's epilepsy drug candidates, XEN901, is eligible for up to $1.7 billion in milestone payments from Neurocrine, should the drug prove to be a success. In comparison, Xenon reported just $3.5 million in third-quarter revenue.

With that much potential upside from just one of Xenon's epilepsy candidates, the optimism surrounding this specific biotech stock is justifiably high.

See the article here:
3 High-Risk, High-Reward Stocks That Have Massive Upside Potential - The Motley Fool

Read More...

Makers of adulterated wine ask customers to check their bottles – The Brussels Times

March 1st, 2020 9:42 am

Photo from Antwerp prosecutor's office

The Dutch makers of the wine branded Black & Bianco have called on anyone who bought the wine to check the bottle to see if it has been tampered with.

Earlier in the week it was announced that a Belgian woman from Puurs in Antwerp province had died after drinking a small amount of the wine. At autopsy it was found that the wine had been adulterated with large doses of MDMA or ecstasy and a similar illicit drug MDA.

The bottle she drank from did not have the brands trademark black cork covered with a black foil bearing the companys name and logo. Police hypothesised the bottle was one of several adulterated as a method of smuggling the rugs into Belgium illicitly.

However no new cases have come to light, despite the fact that the victim died in December, and the news this week was widely covered.

In addition, it is not clear how the bottle could have escaped the hands of the smugglers themselves, and finished with a legitimate client in Belgium.

The wine Black & Bianco RED Merlot Cabernet Sauvignon is not sold in Belgium other than online, although it is on open sale in the Netherlands.

Meanwhile a number of the webshops that had previously carried the wine in question have withdrawn it from sale, while the brand owner said the wine is absolutely still drinkable so long as the cork has not been tampered with.

The telephone here doesnt stop ringing. Many of our clients are naturally asking questions. They want to know whats going on, and if there are possibly other bottles that are not right, said owner Coen Scholders.

I can understand their concern, but our wine can absolutely still be drunk. There is for the time being no indication that more of our bottles have been tampered with and are still in circulation.

Meanwhile it has been revealed that the woman who died was an employee of Finshop, a shop operated by the federal finance ministry which sells off goods seized by customs officers to the general public. Three years ago some customers had to be rushed to hospital after a bottle of wine on sale in one of the shops turned out to contain MDMA in methanol a dangerous form of alcohol that can cause blindness and death.

Since then, however, Finshop stores no longer sell wine to members of the public, the ministry said.

Ministry spokesperson Francis Adyns said it was unlikely the woman had come across the wine in the shop and taken it home. The Antwerp prosecutors office said it had no information to suggest that might have happened, but that all avenues of investigation are being looked at.

Alan HopeThe Brussels Times

Read the original here:
Makers of adulterated wine ask customers to check their bottles - The Brussels Times

Read More...

Frank Buckles, the last soldier to fight in World War I dies at 110 – SOFREP

March 1st, 2020 9:41 am

Frank Buckles lived an amazing and long life.

He joined the Army at only 16 years old to fight in World War I, and later as a civilian, working in the Philippines, was captured by the Japanese at the outset of World War II. He survived three hellish years as a POW at Los Banos POW Camp before being rescued in a raid by American forces.He passed away on February 27, 2011, at the age of 110.

Buckles was born on Feb. 1, 1901, in Bethany Missouri. He was the youngest of five children and the third boy in the household. His familys ancestry traced back to the Revolutionary and Civil Wars. One thing that stood out, however, was that his family genetics were blessed with longevity. As a young boy, he remembered long talks with his grandfather who was born in 1817. His father lived to be 95, his grandmother 96. When he was young he had two aunts that told him to prepare himself for a long life. Both of them lived to be over 100.

When he just a teenager, his family moved from Missouri to Oakwood, Oklahoma, where Buckles went to school, worked in a bank and became an avid wireless operator. With the United States entering World War I, although he was just 16 years old, he tried to enlist. The war, which had started in 1914, was an important event, he remembered later. The world was interested in it. So, I was interested. The Marine Corps turned him down as being too small, sensing that he was underage; the Navy also turned him down ostensibly for having flat feet, also believing him to be too young. But the Army did not. An Army captain asked him for a birth certificate. I explained that when I was born in Missouri, birth certificates were not a public record, Buckles said. It would be in the family Bible. And I said, You wouldnt want me to bring the family Bible down here, would you? He said, Go on, well take you.' So, the U.S. Army hurting for manpower accepted the youngster and he joined on August 14, 1917.

Buckles underwent basic training at Ft. Riley, KS. After basic training, he was trained as a motorcycle rider and ambulance driver. Later in 1917, he was among the first Americans who made their way from England to France. He saw first-hand what combat in the trenches did to the men fighting there as he transported them to hospitals in the rear.

There was never a shortage of blown-up bodies that needed to be rushed to the nearest medical care. The British and French troops were in bad shape even guys about my age looked old and tired. After three years of living and dying inside a dirt trench, you know the Brits and French were happy to see us doughboys. Every last one of us Yanks believed wed wrap this thing up in a month or two and head back home before harvest. In other words, we were the typical, cocky Americans no one wants around, until they need help winning a war.

At the wars end, he helped transport thousands of German POWs back to their homeland. One German soldier gifted him with a belt buckle with the inscription Gott mit uns (God with us). It was a gift that he would keep for the rest of his life. Promoted to Corporal just before he was mustered out in November 1919, Buckles returned to the United States and took part in the dedication of the Liberty Memorial in Kansas City, Missouri where he met the Commander of the American Expeditionary Force General John Pershing.

After the war, despite many veterans having trouble finding work, Buckles never was at a loss for one. He worked in NYC, Toronto, then took a job as a ships purser, and later he ran the Manila office of the American President Lines when the Japanese invaded the Philippines in December 1941 after the bombing of Pearl Harbor. He and many other Americans, both civilian and military, were taken as prisoners of war.

Buckles was a POW for more than three years in the Santo Tomas and Los Baos prison camps. When I got down to 100 pounds, I quit looking at the scales, he said. Like many POWs, he contracted beriberi, a disease caused by malnutrition. To combat the disease, he led a daily calisthenics class for the POWs. I explained to them, he recalled, that were under severe circumstances, but you must keep yourself in shape for when the war is over.

On February 23, 1945, they were all liberated in a daring raid led by the Armys 11th Airborne Division and Filipino guerillas. All 250 of the Japanese guards were killed and the combined rescue force liberated 2147 POWs. Buckles had completed his second war and was now 44 years old.

After the war, he returned to the United States and married Audrey Mayo in 1946. The two bought a 330-acre cattle ranch in West Virginia. They raised a daughter, Susanah, and remained in WV. His wife died in 1999. He continued to drive the tractor on his farmland well into his 100s.

Gary Sinise and Buckles led the Memorial Day Parade of 2007; he was 106 at the time. He was later asked to visit the White House as a guest of President George Bush. Buckles thought that it was an interesting visit. I went to the White House and sat in the Oval Room, he recalled. And here came President Bush and he asked me: Where were you born? And I said, Thats exactly the words that General Pershing used.

Buckles became the honorary Chairman of the World War I Monument Committee and was an outspoken advocate for the dedication of a monument to honor the men who sacrificed so much during the Great War.

We still do not have a national memorial in Washington, D.C. to honor the Americans who sacrificed their lives during World War I. On this eve of Veterans Day, I call upon the American people and the world to help me in asking our elected officials to pass the law for a memorial to World War I in our nations capital. These are difficult times, and we are not asking for anything elaborate. What is fitting and right is a memorial that can take its place among those commemorating the other great conflicts of the past century. On this 92nd anniversary of the armistice, it is time to move forward with honor, gratitude, and resolve.

Buckles died on February 27, 2011, aged 110. He was buried with full military honors in Arlington National Cemetery. As was noted by Paul Duggan, a reporter for the Washington Post:

The hallowed ritual at grave No. 34-581 was not a farewell to one man alone. A reverent crowd of the powerful and the ordinaryPresident Obama and Vice President Biden, laborers and store clerks, heads bowedcame to salute Buckless deceased generation, the vanished millions of soldiers and sailors he came to symbolize in the end.

See the original post here:
Frank Buckles, the last soldier to fight in World War I dies at 110 - SOFREP

Read More...

Stories from the street: This group gathers to write, share stories and celebrate milestones – Idaho Press-Tribune

March 1st, 2020 9:41 am

It was an offer I couldn't refuse.

I recently had the opportunity to attend a monthly meeting of a group of Treasure Valley writers who also happened to be celebrating a milestone: one of their members had just turned 100.

I arrived at the home of Peggy Thiessen in Boise. She and two others Lavaughn Wells and Nancy Ives were waiting for "the birthday girl" to arrive. In the meantime, we began talking.

I found out that this group of "women of a certain age" the youngest, I was told, is 68 get together once a month to share their stories. They all have been working on their autobiographies for a number of years. They follow Frank P. Thomas' book, "How to Write the Story of Your Life."

At each meeting, they read their most recent installments out loud to one another. "An interesting thing is when we read our stories we piggy-back on top of each other," said Thiessen. "There are triggers. We'll think of something in our past that we want our children to know."

The stories are for family members to read so that they can get a glimpse of what their mother's, grandmother's, aunt's or great-aunt's lives were like "before smartphones."

It's a chance to show that there may be more than work or looking at screens, said Ives. "I write my stories in the hopes that my great-nieces will not be too orthodox. I think there's a lot more to life than 8-to-5," she said. "I hope this will give them a spark to get away and see some of the world."

Thiessen, 78, the de facto leader and hostess of the group, said she has been through Thomas' book about four times and each time remembers more stories to write down.

"As you write more and more, you remember more and more," she said. "I tend to write about the funny things instead of the harder things I don't want to think about those things."

Theissen writes all of her tales out in longhand, and her husband, Wayne, types them up for her. They've been married for 57 years, but still "sometimes he learns something new or remembers something he forgot," she said.

Wells, 80, traveled around spending time in Indiana, Ohio and Kentucky before lighting down in Boise in 1986. "My husband, David A. Wells, started the Blue Thunder Marching Band at Boise State," she said. "The first time they were on the field was in 1987."

Lavaughn Wells was also involved in music she had been a teacher in choral music at Nampa High.

Ives, 82, was originally from California and came to Boise by way of Taiwan in 2007. "It was a jump," she said, smiling.

Then the guest of honor arrived. Ethel Farnsworth walked into the room, took a seat and looked around, noting everyone there.

"I've had an interesting life," she said.

Farnsworth, who actually turned 100 on Feb. 9 which also happened to be Ives' birthday held her latest story on her lap. "We're so old, we're turning things over to the historical society," she said, laughing.

Prompted by Thiessen, Farnsworth regaled the group with the story of how she and her husband, Ken Farnsworth Jr., now deceased, came to be the owners of Rhodes Bake-N-Serv, the frozen bread dough company.

There was a Mr. Rhodes, she said, and through a series of fortunate events, he came up with the winning formula for frozen bread dough, much to the delight of homemakers everywhere.

"Mr. Rhodes had found this recipe in the drawer of a cabinet," said Ethel. He handed the it over to his ingenious nephews who began perfecting the process.

Ethel's husband, Ken, who had started a food brokerage business, sort of stumbled onto his bread destiny.

He found Rhodes Bread while traveling in northern Idaho, said Ethel. "He saw some women, who he knew were home bakers, waiting at a grocery store for the bread truck to come in." Intrigued, Ken Farnsworth waited, too. When the truck arrived, it wasn't at all what Farnsworth had imagined: it was a small truck with two college-aged young men handing out frozen loaves of bread dough to the excited women who took the dough home and made fresh "homemade" bread.

Not what he thought, no, but Ken Farnsworth was mightily impressed.

"He immediately went to Portland to meet Mr. Rhodes," said Ethel. "In time, Ken convinced (Mr. Rhodes) he could do a good job with Rhodes bread and he added it to his brokerage and he eventually bought the business," she said.

Do you LOVE local news? Get Local News Headlines in your inbox daily.

Thanks! You'll start receiving the headlines tomorrow!

Ken Farnsworth became the owner but always remained faithful to the bread basics started by Rhodes, who had been a strict vegetarian and humanitarian. "Herbert Cecil Rhodes founded Rhodes Bake-N-Serv in 1958," it says on the company website. "He was a man with high standards and personal principles. ... He did not allow any preservatives to be added to Rhodes White Bread Dough or White Roll Dough. The flour he selected also had to be of the highest quality, unbleached, and have a high-protein content.

Ethel, who was a home economist, published a number of frozen bread dough recipe books for the company, but the most requested recipe through the years is the Butterscotch Bubble Loaf.

Today, the company is run by Kenny Farnsworth, their oldest son. "He's doing such a good job, Rhodes is in all 50 states and he's working on Hawaii," Ethel said.

Looking over her life, Ethel talked about some of the highlights, including her eight children, 16 grandchildren, "and who knows how many great-grandchildren," plus some great-great grandchildren.

After moving from Massachusetts to Morningside Park in Los Angeles, The Farnsworths "found" Boise, she said, in 1959.

"My husband was traveling the 13 western states and he always liked Boise, he found it so friendly," Ethel said. "One day he called and said, 'I bought you a house on Owyhee Street in Boise, Idaho.' I said 'get me a map,'" she said laughing.

She taught foods classes at Boise State University for two years until "they decided (teaching) the classes was too expensive maybe they had to buy a new stove or something," she said, laughing.

She was moved over to The Learning Center in 1976 or '76, she said, where she worked with some of the community's earliest refugee population. "It was the fall of Saigon and people from Vietnam were coming in to Boise. I was in charge of the refugee center," she said.

Farnsworth still goes on walks every day "when the sun shines," works out with her exercise programs on Tuesdays and Thursdays and plays Mahjong twice a month.

To what does she owe her longevity?

She thinks a moment. "I would just say it's just genetics," she said with a smile.

"We're still pretty active old broads."

Know somebody with a story to tell? A neighbor, friend? Someone youve met in school, at church or the grocery store? Send your story ideas to jhuff@idahopress.com, or call 208-465-8106 or 208-871-0911.

Originally posted here:
Stories from the street: This group gathers to write, share stories and celebrate milestones - Idaho Press-Tribune

Read More...

TO YOUR HEALTH: Inflammation can drive triple-negative breast cancer – Dover Post

February 29th, 2020 7:48 am

Study at ChristianaCare Cawley Center for Translational Cancer Research

While radiation is successfully used to treat breast cancer by killing cancer cells, inflammation caused as a side-effect of radiation can have a contrary effect by promoting the survival of triple-negative breast cancer cells, according to research published online in the International Journal of Radiation Biology by Jennifer Sims-Mourtada, Ph.D., director of Translational Breast Cancer Research at ChristianaCares Helen F. Graham Cancer Center & Research Institute.

Accounting for 15-20% of all breast cancers, triple-negative breast cancer is faster growing than other types.

Sims-Mourtadas latest study, Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells, brings scientists closer to understanding the mechanisms behind this aggressive and hard-to-treat cancer. It shows that inflammation caused by radiation can trigger stem-cell-like characteristics in non-stem breast cancer cells.

This is the good and the bad of radiation, Sims-Mourtada said. We know radiation induced inflammation can help the immune system to kill tumor cells thats good but also it can protect cancer stem cells in some cases, and thats bad.

She added, Whats exciting about these findings is were learning more and more that the environment the tumor is in its microenvironment is very important. Historically, research has focused on the genetic defects in the tumor cells. Were now also looking at the larger microenvironment and its contribution to cancer.

The term triple-negative breast cancer refers to the fact that the cancer cells dont have estrogen or progesterone receptors and also dont make too much of the protein called HER2. The cells test negative on all 3 tests. These cancers tend to be more common in women under age 40, who are African-American, Latina or who have a BRCA1 mutation.

My work focuses on cancer stem cells and their origination, Sims-Mourtada said. They exist in many cancers, but theyre particularly elusive in triple-negative breast cancer. Their abnormal growth capacity and survival mechanisms make them resistant to radiation and chemotherapy and help drive tumor growth.

She and her team applied radiation to triple-negative breast cancer stem cells and to non-stem cells. In both cases, they found radiation induced an inflammatory response that activated the Il-6/Stat3 pathway, which plays a significant role in the growth and survival of cancer stem cells in triple-negative breast cancers. They also found that inhibiting STAT3 blocks the creation of cancer stem cells. As yet unclear is the role IL-6/STAT3 plays in transforming a non-stem cell to a stem-cell.

For women living in Delaware, Sims-Mourtadas research is especially urgent: The rates of triple-negative breast cancer in the state are the highest nationwide.

At ChristianaCare, we are advancing cancer research to help people in our community today, while we also advance the fight against cancer nationwide, said Dr. Nicholas J. Petrelli, Bank of America endowed medical director of the Helen F. Graham Cancer Center & Research Institute. Dr. Sims-Mourtadas research is a dramatic step toward better treatments for triple-negative breast cancer.

To advance her research on inflammation, last year Sims-Mourtada received a $659,538 grant from the Lisa Dean Moseley Foundation. The three-year grant will enable her and her team at the Cawley Center for Translational Cancer Research to continue investigating the role of cells immediately around a tumor in spurring the growth of triple-negative breast cancer and a possible therapy for this particularly difficult cancer.

Our next step is to understand the inflammatory response and how we might inhibit it to keep new cancer stem cells from developing, Sims-Mourtada said.

Sims-Mourtadas research team previously identified an anti-inflammatory drug, currently used to treat rheumatoid arthritis, that has the potential to target and inhibit the growth of cancer stem cells and triple-negative breast cancer tumors. That research could set the stage for clinical investigation of the drug, alone or in combination with chemotherapy, to improve outcomes for patients with triple-negative breast cancer.

The rest is here:
TO YOUR HEALTH: Inflammation can drive triple-negative breast cancer - Dover Post

Read More...

A new approach to both high safety and high performance of lithium-ion batteries – Science Advances

February 29th, 2020 7:48 am

RESULTS

As a proof of concept, we prepare a baseline cell composed of a standard electrolyte, 1 M LiPF6 in ethylene carbonate (EC)/ethyl methyl carbonate (EMC) (3/7 wt) + 2 weight % (wt %) vinylene carbonate (VC), and a graphite anode and an NCM622 cathode. Protective layers of solid electrolyte interphase (SEI) on graphite and cathode electrolyte interphase (CEI) are formed during initial charge/discharge cycles. To yield low DCR and hence high power, these interfacial layers are usually thin, lacking sufficient density and resilience to resist decomposition under abuse conditions, to suppress continuous reaction of the solvent EC in the SEI, or to hinder continuous oxidation of EC with oxygen released from cathode materials in the CEI, thereby leading to Li consumption and loss of cell capacity. In contrast, in SEB cells, we create highly stable, flame-retardant EEIs through the addition of a small amount of TAP in the standard electrolyte. This electrolyte modification is accompanied by the simultaneous reduction of EC content, i.e., EC/EMC (1/9 wt) + 2 wt % VC, intended for further reduction in gas production via side reactions. In this work, we present results for three prototype SEB cells, identified as SEB-1, SEB-2, and SEB-3 and corresponding to 0.5, 1, and 1.5 wt % TAP, respectively. The charge-transfer resistance of the SEB cells, measured by electrochemical impedance spectroscopy (EIS), increases by 3 to 5 as compared to the baseline cell without the electrolyte additives, as shown in Fig. 2A. The high impedance comes from the polymerization of TAP molecules that form thick and dense interfacial films at the surfaces of both the anode and cathode (2). On the anode side, the film serves as an enhanced SEI layer to stabilize further growth. On the cathode side, the film hinders EC in the electrolyte from reacting with lattice oxygen on the NCM surface at high temperature or high voltage (3), as shown schematically in Fig. 2B.

(A) Nyquist plots showing measured charge-transfer resistances of SEB cells versus the baseline LIB cell. (B) Schematic showing the in situ formed interfacial layers on the surface of graphite and NCM particles. The enhanced SEI layer on graphite slows down EC transport though the film and suppresses further SEI growth. The CEI layer hinders EC oxidation with lattice oxygen over the NCM surface at high temperatures or high voltages. (C and D) Cell voltage and temperature evolutions during nail penetration of a SEB cell and the baseline LIB cell along with qualitative temperature distributions. Both cells are 2.8-Ah pouch cells composed of the same graphite anode and NMC622 cathode materials. The baseline LIB cell is filled with a standard electrolyte: 1 M LiPF6 in EC/EMC (3/7 wt) + 2 wt % VC. The SEB cell has the electrolyte of 1 M LiPF6 in EC/EMC (1/9 wt) + 2 wt % VC with TAP as electrolyte additive. RT, room temperature.

PolyTAP and its composites are flame-retardant materials. In addition, the PolyTAP has electrically insulative properties and stability at elevated temperatures (4). All these properties make PolyTAP well suited to enhance the safety of SEB cells under abuse conditions. This is confirmed by nail penetration tests shown in Fig. 2C, where the temperature rise is only 100C (without cell deformation, smoking, or fire) versus almost 1000C (catching fire) in the baseline case (Fig. 2D). The superior safety performance of the SEB cell is further illustrated by the electrical performance of the cell during nail penetration. For the baseline cell, the cell voltage decreases to 0.1 V within 5 s after the nail penetration. The sharp voltage drop indicates that the shorting current is extremely high due to low internal resistance of the baseline cell. In contrast, the voltage of the SEB cell drops from 4.171 to 3.085 V within 5 s after penetration, showing a slow and controlled discharge due to the high internal resistance of the SEB cell. The substantially higher resistance in the SEB cell than the baseline is caused by the electrically nonconductive layers formed on the surface of the graphite and NCM particles, as schematically shown in Fig. 2B.

The stability and safety of SEB cells are further evident in high-voltage charge and high-temperature calendar life tests (figs. S1 and S2). The SEB cells can undergo 1254 exposures to high-voltage abuse [constant current (CC) charge to 4.4 V, constant voltage (CV) to C/20] at 40C with a capacity retention of 80%, whereas the baseline cell sustains only 40 cycles at the same capacity loss and operating temperature, indicating that the SEB cell is >30 more stable and hence safer than the baseline cells under high-voltage charging conditions. Calendar life testing further shows that the passivated SEB cells can effectively suppress self-discharge. The self-discharge current is measured by holding the cell voltage constant at a required value, such as 4.187 V for 100% state of charge (SOC). Both baseline and SEB cells display a fast decrease of self-discharge current density in the beginning of calendar aging due to anode SEI layer growth. Fresh SEB cells show self-discharging currents ~5 lower than the baseline cell at room temperature and 50% SOC, 6 lower at room temperature and 100% SOC, and ~7 lower at 60C at both 50 and 100% SOC. After 60 days of storage, the self-discharge current begins to plateau; however, the self-discharge current in the SEB cell is still 2 lower than that in the baseline cell at room temperature and 50% SOC and 3 lower at room temperature and 100% SOC. The self-discharge becomes 4 lower at high temperature (60C) at both 50 and 100% SOC, indicating that at elevated temperatures, the SEB cells maintain superiority in calendar life over the baseline cell.

A distinctive feature of SEB cells is high power on demand. When batteries are not in operation, SEB cells are left idle at room temperature, exhibiting high stability and safety. However, upon operation, a SEB cell switches to high-reactivity conditions through rapid thermal stimulation. This can be illustrated through DCR, which is inversely proportional to power performance. Here, DCRs upon discharge and charge for SEB and baseline LIB cells are measured at 50% SOC by a 10-s hybrid pulse power characterization (HPPC) method. As expected, the DCR values increase substantially by adding a small amount of TAP in the electrolyte, as shown in Fig. 3 (A and B), which also demonstrates that adding more TAP in SEB-3 (e.g., 1.5 wt %) results in a further increase in DCR, owing to the formation of thicker protective layers.

(A and B) DCRs of discharge and charge, respectively, at 50% SOC for SEB cells versus the baseline LIB cell. (C) Relative discharge power (DCRbaseline@RT/DCR) of a SEB cell versus the baseline LIB cell. (D) Relative reactivity (Rct,baseline@RT/Rct) of a SEB cell versus the baseline LIB cell, showing that SEB cells operated at appropriate elevated temperatures, e.g., SEB-3 at 50C, can deliver sufficient power at all ambient temperatures (labeled as line a), that SEB cells are 5 safer and less aging at room temperature (labeled as line b), and that SEB cells are 2.6 less prone to thermal runaway at 60C (labeled as line c).

Figure 3C shows the relative power of SEB cells versus the baseline LIB, where the power of the baseline cell at room temperature is normalized to be unity, thus demonstrating that SEB cells can provide sufficient, higher power by operating at higher temperatures. At 50% SOC, SEB-1 operated at 29.2C provides the same power as the baseline cell at room temperature. The safest cell, SEB-3, with 1.5 wt % TAP additive requires an operation temperature of 44.6C to deliver the same power as the baseline cell at room temperature. The baseline cell has a narrow temperature window of 15 to 35C, whereas the SEB cells have much higher maximum operating temperature without becoming excessively reactive. Thus, the necessity of higher temperature operation for power recovery does not pose an issue for SEB cells. At 50% SOC, the discharge power boost over the baseline Li-ion cell is 2.05, 1.81, and 1.39 for the SEB-1, SEB-2, and SEB-3, respectively (Fig. 3C). Moreover, at the ambient temperature of 0C, the baseline LIB cell has a relative power of 0.38, while SEB-2 has a relative power of 1.81 when operated at 60C [it takes 30 s to heat up a cell from 0 to 60C at a speed of 2C/s, typical of the self-heating structure of Wang et al. (1)]. This is ~5 boost in power over the LIB cell for SEB cells working in the freezing environments. Generally, SEB cells perform independent of ambient temperatures or weather, as they are always heated up in a matter of seconds and operate at a constant elevated temperature. Although heating a cell to an elevated temperature consumes cell energy, the total deliverable energy of a cell, counterintuitively, is not reduced. As shown in fig. S3, the C/3 discharge energy was 9.62 watt-hours (Wh) for the baseline cell at room temperature and 10.15 Wh for the SEB-3 cell at 60C. According to our previous work (1), it takes ~1% cell energy for a 10C temperature rise, meaning that the SEB-3 cell needs 3.5% of its energy for heating from 25 to 60C; the remaining discharge energy is thus 9.79 Wh, which is 2% higher than that of the baseline cell at room temperature.

As mentioned, such rapid heating is achieved through the insertion of a micrometer-thick nickel sheet. The impact of this additional component on cell power density can be evaluated through Eq. 1, where m is the mass of the given cell and the ratio of discharge power evaluated through HPPC is inversely proportional to the ratio of DCRs(Power Density)SEB(Power Density)baseline@RT=(DCRbaseline@RTDCRSEB@60C)(mbaselinemSEB)(1)

The addition of the nickel foil increases cell mass by 1.3%, while the ratio of DCRs in Eq. 1 is the relative power presented in Fig. 3C at 60C. On the basis of these values, the power density is not reduced but rather increased by a factor of 2.02, 1.79, and 1.37 in the case of SEB-1, SEB-2, and SEB-3, respectively. Thus, in the case of SEB-3 with the highest internal resistance, the power density is still 37% higher than the baseline cell operated at room temperature.

Figure 3D presents the relative interfacial reactivity as derived from the charge-transfer resistance of EIS results. This further confirms that increased operational temperature effectively decreases the charge-transfer resistance of SEB cells and consequently increases the cell reactivity and power. The reactivity boost over the baseline LIB cell is 2.06 for SEB-2. Overall, both relative power and relative reactivity illustrate the ability of SEB cells to achieve high power on demand. On the other hand, the values of relative reactivity of these two cells shown in Fig. 3D indicate that the SEB cell will be 5 safer and undergo 5 less aging at room temperature, which is supported by self-discharge and capacity retention tests displayed in fig. S2. Furthermore, the comparison of relative reactivity for the two cell types at 60C indicates that the SEB cell is more than 2 less prone to thermal runaway.

Beyond safety and high power, there is an ever-increasing need for long cycle life of LIBs. Low-reactivity SEB cells built with highly stable materials offer longer calendar life (fig. S2), evident from the slow capacity fade when the battery is in idle conditions at room temperature. At elevated temperatures, cycling of SEB cells is also stable. Figure 4A compares capacity retention of the baseline cell with SEB cells during cycling at 60C of 1C CC charge to 4.2 V CV charge till C/20 and then 1C discharge to 2.8 V. Clearly, the SEB cells outperform the baseline cell as evidenced by a 20% capacity loss at 481 cycles with visible signs of cell deformation due to gas evolution and graphite anode swelling for the baseline cell, while SEB-3 can achieve 2821 cycles before reaching 20% capacity loss. This corresponds to ca. 6 improvement in cycle life. In addition, SEB-3 achieves 4014 cycles at 75% capacity retention while still showing signs of a healthy cell capable of cycling stably (no perceptible gassing or lithium plating). The average discharge capacity of these 4014 cycles is 84.2% of an equivalent full cycle (EFC). Assuming a 153-mile driving range per EFC for an electric vehicle (e.g., 2019 BMW i3), the 4014 cycles mean >517,000 miles of lifetime. That is more than 5 the warranty for commercial electric cars (e.g., BMW i3, 70% capacity for 8 years or 100,000 miles). Improvement of cell lifetime can be further demonstrated by considering the rate of capacity fade during calendar aging at room temperature (i.e., the stable state), which is 7 lower than that at 60C (the reactive state). The SEB cell will only be heated to the reactive state for situations requiring high power or fast charging. The greater part of its lifetime (>90%) would be spent in idle conditions (the stable state). Therefore, in the field, the SEB cycle life is expected to extend much beyond 4014 cycles before reaching 25% capacity loss.

(A and B) Capacity retention and DCR of the SEB cells versus the baseline LIB cell during cycling at 60C. The cells are charged with CCCV protocol at 1 C to 4.2 V with a cutoff current of C/20 and then discharged at 1 C to 2.8 V. (C and D) Discharge curves of the fresh SEB cell versus aged cell.

The tremendous extension of cycle life of the SEB over the baseline cell may stem from the denser and more stabilized SEI layer formed on graphite particles and CEI layer on NCM622 particles in the presence of the electrolyte additives. For the baseline cell, the nickel-rich NCM particles are prone to microcracks along grain boundaries (5, 6) that provide gaps for electrolyte penetration and lead to more severe electrolyte oxidation and rock salt formation (7). Particle cracking also sets free new, fresh surface area from which oxygen can be released (8). The microcracks on NCM622 particles for the baseline cell are observed after only 50 cycles (Fig. 5D). The formation of cracks becomes much more notable throughout the micrograph domain after 956 cycles (Fig. 5F). For the SEB cells, cracks on NCM particles are not observed at 50 cycles, and a small amount of cracks are observed after 4021 cycles (Fig. 5J). The presence of microcracks not only causes a loss of contact but also accelerates NCM capacity fade. For the SEB cells, the polymer coating from TAP likely forms a robust CEI, reducing formation of microcracks (Fig. 2B). This is also evidenced by optical images (fig. S4) and no observable cell deformation or swelling after 4021 cycles even at an elevated temperature of 60C.

(A) Pristine anode. (B) Pristine cathode. (C) Baseline anode after 50 cycles. (D) Baseline cathode after 50 cycles. (E) Baseline anode after 956 cycles. (F) Baseline cathode after 956 cycles. (G) SEB-3 anode after 50 cycles. (H) SEB-3 cathode after 50 cycles. (I) SEB-3 anode after 4021 cycles. (J) SEB-3 cathode after 4021 cycles. ETD, Everhart-Thornley Detector; HV, electron accelerating voltage; WD, working distance; HFW, horizontal field width.

The use of the TAP additives altered the EEI compositions markedly. We performed x-ray photoelectron spectroscopy (XPS) on the graphite and NCM electrodes after 4021 cycles and compared the EEI structure of the samples from the baseline cell after 956 cycles. At the graphite anode, the TAP-containing electrolyte-derived SEI contains high concentrations of C, O, and P elements, compared to the control sample of the baseline cell (Fig. 6 and fig. S5). In addition, a higher content of CC species in the entire C-containing species was also found in the TAP-containing electrolyte-derived SEI, suggesting the decomposition of the TAP at the anode (fig. S5). Meanwhile, the composition of the cathode CEI was also changed. With the TAP additive, the SEI layer has more C, P, and F and less Li and O, compared to the baseline SEI (Fig. 6 and fig. S5). High contents of LiF and P-containing species (OPO, LixPyOFz, and LixPyFz) (9) were found in the cathode CEI layer, owing to the use of the TAP additive (Fig. 6). A detailed peak interpretation is as follows: peaks at 284.6, 286.1, 288.8, and 290.1 eV in the C 1s spectrum are attributed to CC, CO, OCO, and poly(OCO) (10), respectively; peaks at 684.6 eV in the F 1s spectrum are attributed to LiF; peaks at 686.9 eV in the F 1s spectrum and 136.7 eV in the P 2p spectrum are attributed to OPO and LixPyOFz; and peaks at 686.3 eV in the F 1s spectrum and 134.5 eV in the P 2p spectrum are attributed to LixPyFz. In comparing O 1s spectrum of the aged baseline (956 cycles) and SEB-3 electrodes (4021 cycles), the peak at 529.2 eV for SEB-3 cathode is effectively eliminated in comparison to that for the baseline cathode (Fig. 6). This indicates that less lattice oxygen of NCM622 is detected for SEB-3 cathode attendant to a relatively thicker CEI layer. This is consistent with the thicker CEI layer detected by Xia et al. (2) on the coated NMC442 surface in the presence of TAP additive. Thus, the XPS result confirms that the TAP additive leads to a thick CEI layer and, in consequence, slower crack evolution, less gas generation, and longer cycle life.

The graphite and NCM622 electrodes are taken from the baseline cell after 956 cycles and the SEB-3 cell after 4021 cycles.

The three SEB cells show very close rates of capacity fade within 1000 cycles (Fig. 4A). Beyond 1000 cycles, SEB-3 shows a much lower rate of capacity fade than the other two SEB cells, as expected from its lowest reactivity. In comparison with the baseline cell, the stability and long cycle life of SEB cells are clearly evident, the reasons of which can be delineated from the differences in the capacity retention trend at various stages of aging. For the baseline cell, we see a sharp decrease in C/3 capacity retention during the initial stage and a slow decrease in the secondary stage. This is primarily attributed to the loss of lithium inventory during the quick and slow growth of the SEI layer. For the SEB cells, the capacity fade is linear with cycle number, indicating that there is no quick growth in the initial stage of aging as SEI layer growth is suppressed by in situ formation of the flame-retardant protective layer. Moreover, a sharp, nonlinear capacity loss due to lithium plating can usually be observed in the baseline cell at room temperature and at low temperatures in final stages of cell aging (11). In all SEB cells operated at 60C, this lithium plating-induced capacity loss is, however, absent, indicative of no lithium plating in SEB cells. The SEB cell free of Li plating offers a significant improvement in safety over conventional LIB cells.

There is another advantage of SEB cells promising for ultralong cycle life when deployed in the field. While conventional LIB cells undergo a large environmental temperature swing, the SEB cells almost always operate at a single, constant temperature (say 60C) regardless of ambient temperatures and after an extremely short period of initial transition by self-heating (on the order of tens of seconds). The latter feature guarantees minimal damage of battery materials in SEB cells caused by wide temperature variations.

For the baseline cell, the capacity loss at elevated temperatures is mainly due to SEI growth on the anode side and solvent oxidation on the cathode side. As a consequence, the DCR increases markedly with cycle number (Fig. 4B). In the case of SEB cells, the DCR of the fresh cell is initially much larger than the baseline cell; however, its rate of increase is much slower due to the protective coating on both the anode and cathode (Fig. 2B). Figure 4 (C and D) shows discharge curves of the fresh SEB cell versus the aged cell, respectively. Because of its DCR increase with cycle number, SEB-3 shows slight power fade after 2821 cycles at 60C. In contrast, the baseline cell shows a drastic DCR increase and, hence, substantial power loss within only 556 cycles (fig. S6). For all the SEB cells with TAP additive, their DCRs increase linearly and increased additive content leads to higher DCR in fresh cells but slower DCR evolution with cycle number (Fig. 4B). The SEB cells do not produce gas during cycling tests, yielding more safety than the baseline cell. In addition, cells containing TAP produce less gas during formation than the baseline cell (2, 12).

Because of the high-voltage tolerance of SEB cells, when charged to a high voltage of 4.4 V as compared to 4.2 V, the SEB cell discharge capacity increases 12.7%, and its discharge energy increases 14.5% (fig. S1B). Thus, the high-voltage tolerance can be used to increase cell energy density.

The electrolytes for SEB cells were formulated by reducing EC content and adding TAP as an additive. Although EC is an essential solvent for SEI layer formation, it also leads to gas generation, especially at high voltage (13). Calendar aging testing shows that high-temperature and high-SOC conditions accelerate capacity fade and increase in internal resistance while also promoting gas generation. SEB cells initially contains 10 wt % EC in the electrolyte. Some EC is consumed during the formation cycle, resulting in an EC content much less than 10% in formed SEB cells. This is advantageous since the rate of gas generation in an EC-less electrolyte would be lower than that in an electrolyte with high EC content.

With the introduction of new materials into the electrolyte, the effect on cell cost, weight, and fabrication should be evaluated. The electrolyte additive, TAP, has a comparable price and density when compared to current standard solvents; thus, no notable material cost difference is expected with the introduction of SEB electrolytes. Unlike superconcentrated electrolytes (14), the electrolytes with TAP do not increase the viscosity compared to the standard electrolyte. From a fabrication perspective, the SEB electrolytes will also add no additional cost due to the similarity in processing during and after introduction into a cell.

Last, the SEB cells offer an important benefit associated with thermal management of a battery pack. When high power is required, the SEB cells are to be heated internally (1) and operated at elevated temperatures. Assuming the environmental temperature is 25C, and the SEB and baseline cells operate at 60 and 30C, respectively, the SEB provides a temperature difference driving heat dissipation that is 7 larger than the baseline case. Further, the SEB cell has lower DCR at its operational temperature of 60C (17.1 ohmcm2 for SEB with 1 wt % TAP) than the baseline cell at 30C (25.3 ohmcm2), indicating ~1.5 lower heat generation at the same current. The combination of these two factors eases the burden of thermal management by a factor of approximately 10 for SEB cells.

We fabricated 2.8-Ah pouch cells using LiNi0.6Co0.2Mn0.2O2 (Umicore) for cathodes and graphite (Nippon Carbon) for anodes. The capacity ratio of negative to positive electrode, or NP ratio, was designed at 1.2. The 2.8-Ah pouch cell contains a stack of 20 anode and 19 cathode layers. A Celgard-2325 separator of 25 m in thickness was used. The loadings of NMC622 on the positive electrode and graphite on the negative electrode were 10.5 and 6.6 mg/cm2, respectively.

The cathodes were prepared by coating an N-methyl-2-pyrrolidone-basedbased slurry onto 15-m-thick Al foil, whose dry material consists of NCM622 (91.5 wt %), Super-P (TIMCAL) (4.1 wt %), and polyvinylidene fluoride (Arkema) (4.4 wt %) as a binder. The anodes were prepared by coating deionized waterbased slurry onto 10-m-thick Cu foil, whose dry material consists of graphite (95.4 wt %), Super-P (1.0 wt %), styrene-butadiene rubber (Zeon) (2.2 wt %), and carboxymethyl cellulose (Dai-Ichi Kogyo Seiyaku) (1.4 wt %).

One molar of LiPF6 dissolved in EC/EMC (3:7 by wt) + 2 wt % VC was used as control electrolyte (BASF). One molar of LiPF6 dissolved in a mixture of EC/EMC + 2 wt % VC was mixed in-house. To build SEB cells, 0.5 to 1.5 wt % TAP were mixed into the conventional electrolyte as additives.

Each pouch cell has a 110 mm 56 mm footprint area, weighs 63 g, and has 2.8-Ah nominal capacity with a specific energy of 166 Wh/kg and an energy density of 310 Wh per liter. Discharge performance of the baseline and SEB cells at room temperatures is shown in fig. S7 as a function of C-rate.

Cycle aging tests of the pouch cells were performed using a Land instrument battery testing system (Model CT2001B, Land Instruments). A forced-air oven was used to control different ambient temperatures. For each aging cycle, the cell was charged to 4.2 V at a constant current of 2.8 A (1C-rate) and then charged at a constant voltage of 4.2 V until the current decreased to 0.14 A (C/20). After resting for 5 min, the cell was discharged to 2.8 V at a constant current of 2.8 A (1C-rate) followed by a final rest period of 5 min. When the aging cycle number reached a specific value (e.g., 403, 1006 cycles), the cell was cycled at a charge and discharge rate of C/3 to determine the capacity (designated as C/3 capacity) of the cell. For impedance tests at different temperatures, the cells were fully charged and then discharged at a rate of C/3 to 90% SOC. Impedance testing was performed with an AC voltage amplitude of 5 mV in the frequency range of 50 kHz to 0.005 Hz. For DCR test, the cells were fully charged and then discharged to 50% SOC at C/3-rate. A discharge rate of 5C and a charge rate of 3.75C were used to determine the value of DCRDischarge and DCRCharge.

Calendar aging tests were performed at different ambient temperatures and SOCs. The forced-air oven was used to control different ambient temperatures. The cell voltage was kept constant, and the current was collected. When the calendar aging time reached a specific value (e.g., 25, 60, 120, and 180 days), the cell was cycled at a charge and discharge rate of C/3 to determine capacity of the cell. Then, impedance and DCR tests were conducted under the same conditions as that for the cycle-aged cells.

For the nail penetration test, the cell was fully charged (1C CCCV charge with a cutoff voltage of 4.2 V and a cutoff current of C/20). Thermocouples were placed at 10 mm to the geometry center of the cell and at the negative tab of the cell. The nail diameter is 5 mm, made of heat-resisting steel (point angle of the nail is 60; nail surface is clean, without rust or oil). Rate of penetration was at 30 mm/s; the nail penetrated through the geometrical center of the electrode plane perpendicularly and stayed inside the cell. The observation time was 1 hour until the cell cooled down and the cell voltage dropped to nearly zero.

The SEM and XPS analyses were performed by first extracting the electrode samples from the fully discharged graphite/NCM622 pouch cells after cycling and washing 3 with EMC. XPS tests were conducted on a PHI VersaProbe II Scanning XPS Microprobe. The samples were loaded in a glove box and transferred into the instrument through a vacuum transfer vessel. SEM imaging was performed on an FEI Nova NanoSEM 630 SEM instrument.

Acknowledgments: Funding: This work was partially supported by U.S. Department of Energys Office of Energy Efficiency and Renewable Energy under award number DE-EE0008447. Author contributions: S.G. and C.-Y.W. developed the concept and wrote the manuscript. S.G. and R.S.L. designed and built the cells. S.G. built the test stand and carried out the performance characterization. T.L. carried out the nail penetration test. Y.L. performed the impedance analysis. Y.G. and Daiwei Wang carried out the XPS and SEM analysis. All authors contributed to development of the manuscript and to discussions as the project developed. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Excerpt from:
A new approach to both high safety and high performance of lithium-ion batteries - Science Advances

Read More...

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2020 Swot (Strengths, Weaknesses, Opportunities, And Threats) analysis By…

February 29th, 2020 7:48 am

Chemotherapy Induced Peripheral Neuropathy Treatment market Research Report 2020 offers a comprehensive analysis of the market growth drivers, trends, opportunities, prospects, drivers and restrictions inside the market. The report emphasizes to meet the requirement of customers by providing complete knowledge of the Chemotherapy Induced Peripheral Neuropathy Treatment Industry. This carefully organised report is formulated by industry experts and professional experts, in terms of demand and supply, cost organization, barriers and challenges, product category, crucial market players, technology, regions, and applications.

The Chemotherapy Induced Peripheral Neuropathy Treatment market study is based on historical information and present market requirements. As well as includes different business approaches preferred by the decision-makers. That enhanced the Chemotherapy Induced Peripheral Neuropathy Treatment industry growth and make a phenomenal stand in the industry. The market will raise with a prominentCAGRby 2020 to 2025.

Download Free Sample Report

https://www.reportspedia.com/report/life-sciences/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers,-regions,-type-and-application,-forecast-to-2025/49368 #request_sample

Furthermore, it also evaluates the most recent improvements while estimating the growth of theleading playerslike

Aptinyx Inc, Sova Pharmaceuticals Inc, MAKScientific LLC, Asahi Kasei Pharma Corp, PledPharma, Regenacy Pharmaceuticals, Immune Pharmaceuticals Inc, Nemus Bioscience Inc, Metys Pharmaceuticals AG, DermaXon LLC, WinSanTor, Kineta Inc, Solasia Pharma K.K., Apexian Pharma, Krenitsky Pharmaceuticals Inc, PeriphaGen,

Segmentation by Product Type

By TypeChemotherapy Induced Peripheral Neuropathy Treatment market has been segmented into Calcium Channel 2-delta Ligands, Antidepressants, Opioids, Others, etc.

Segmentation by Application/ End uses:

By Application Chemotherapy Induced Peripheral Neuropathy Treatment has been segmented into Platinum Agents, Taxanes, Vinca Alkaloids, Others, etc.

Regional Analysis for Chemotherapy Induced Peripheral Neuropathy Treatment Market:

North America (the United States, Canada & Rest of the countries)

Europe (Germany, The UK, France, Netherlands, Italy, Spain & the rest of the countries)

Asia-Pacific (China, Japan, Korea, India, & rest of the countries)

Middle East & Africa (South Africa, Israel, UAE & rest of the countries)

South America (Brazil, Colombia, Argentina & the rest of the countries)

Ask For discount

https://www.reportspedia.com/discount_inquiry/discount/49368>

What is the regional structure of the market? Our analysis-

The Chemotherapy Induced Peripheral Neuropathy Treatment Industry report analyses footprint of every product and its significance analyzes examine each geographical segment of the market with import, export, consumption, and production in these regions to provide a complete understanding of the Chemotherapy Induced Peripheral Neuropathy Treatment market

In addition, the Chemotherapy Induced Peripheral Neuropathy Treatment Industry report covers an analysis of different products available in the global market built on production, volume, revenue, and cost and price structure. The Chemotherapy Induced Peripheral Neuropathy Treatment Market report also highlights key strategies that proved to be profitable for the business in-line with the policies involved in business expansion, partnership deals, composition, and new product/service launches.

YEARS CONSIDERED FOR THIS REPORT:

Historical Years:2015-2019

Base Year:2019

Estimated Year:2020

Forecast Period:2020-2025

DEFINITE SEGMENTS OF GLOBAL Chemotherapy Induced Peripheral Neuropathy Treatment INDUSTRY:

The analysis highlights a region-wise as well as a worldwide study of the Chemotherapy Induced Peripheral Neuropathy Treatment market. Proportionately, the regional study of the industry comprisesJapan, South East Asia, India, the USA, Europe, and China.Moreover, the report reviews an in-depth market analysis of distinct manufacturers and suppliers. It explainsindustry chain structure, competitive scenario, and study of Chemotherapy Induced Peripheral Neuropathy Treatment industry costin detail. It evenly analyzes global industry size pursued by forecast period (2020-2025) and environment.

Ask For Report Customization

https://www.reportspedia.com/inquiry/customization/49368

The analysis covers basic information about the Chemotherapy Induced Peripheral Neuropathy Treatment product likeindustry scope, segmentation, anoverviewof the market. Likewise, it providessupply-demand data, investment feasibleness, and elements that limiting the growth of an industry. Predominantly, it helps product demand, annual revenue and growth prospects of the industry. The foreseen Chemotherapy Induced Peripheral Neuropathy Treatment market regions along with the present onesassist leading vendors, decision-makers, and viewers/readersto plan effective business strategies respectively.

KEY TOPIC COVERED

Growth Opportunities

Market Growth Drivers

Leading Market Players

Market Size and Growth Rate

Market Trend and Technological

Company Market Share

TOC OF Chemotherapy Induced Peripheral Neuropathy Treatment MARKET REPORT INCLUDES:

1 Industry Overview of Chemotherapy Induced Peripheral Neuropathy Treatment

2 Industry Chain Analysis

3 Manufacturing Technology

4 Major Manufacturers Analysis

5 Global Productions, Revenue and Price Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment by Regions, Creators, Types, and Applications

6 Global and Foremost Regions Capacity, Production, Revenue and Growth Rate by 2013-2019

7 Consumption Volumes, Consumption Value, Import, Export and Sale Price Analysis by Regions

8 Gross and Gross Margin Analysis

9 Marketing Traders or Distributor Analysis

10 Global and Chinese Economic Impacts on the Chemotherapy Induced Peripheral Neuropathy Treatment Industry

11 Development Trend Analysis

12 Contact information

13 New Project Investment Feasibility Analysis

14 Conclusion of the Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry 2019 Market Research Report Continued

Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

Key questions answered by the Chemotherapy Induced Peripheral Neuropathy Treatment Report:

What are some of the most favourable, high-growth prospects for the global Chemotherapy Induced Peripheral Neuropathy Treatment market?

Which products segments will raise at a faster pace throughout the forecast period and why?

What are the foremost factors impacting market prospects?

What are the driving factors, restraints, and challenges in this Chemotherapy Induced Peripheral Neuropathy Treatment market?

What are the competitive threats and challenges to themarket?

What are the evolving trends in this Chemotherapy Induced Peripheral Neuropathy Treatment market and reasons behind their emergence?

What are some of the changing customer demands in the Chemotherapy Induced Peripheral Neuropathy Treatment Industry market?

Continue

Explore More Information

https://www.reportspedia.com/report/life-sciences/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers,-regions,-type-and-application,-forecast-to-2025/49368 #table_of_contents

See original here:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2020 Swot (Strengths, Weaknesses, Opportunities, And Threats) analysis By...

Read More...

Possible Associations of Vitamin D, Vitamin D-Binding Protein, and Vit | JPR – Dove Medical Press

February 29th, 2020 7:48 am

Asuman Celikbilek

Department of Neurology, Kudret International Hospital, Ankara, Turkey

Correspondence: Asuman CelikbilekKudret International Hospital, Department of Neurology, Ankara 06600, TurkeyTel +90 505 6532615Fax +90 312 229 98 68Email asunebioglu@yahoo.com

We read with great interest the article recently published in Journal of Pain Research by Sari et al,1 examining the effect of vitamin D replacement therapy on neuropathic pain and imbalance in patients with diabetic neuropathy (DN). They found that vitamin D replacement reduced neuropathic pain and improved balance scores in patients with DN. They suggested that a vitamin D replacement schedule might be planned in diabetic patients with vitamin D deficiency in order to resolve neuropathic pain and balance problems. However, we would like to add some points which may be taken into consideration.

View the original paper by Sari and colleagues

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more:
Possible Associations of Vitamin D, Vitamin D-Binding Protein, and Vit | JPR - Dove Medical Press

Read More...

Mersana Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Updates – BioSpace

February 29th, 2020 7:48 am

XMT-1536 Phase 1 dose escalation data update selected for late-breaker oral presentation at upcoming Society of Gynecologic Oncology (SGO) 2020 Annual Meeting on Womens Cancer

XMT-1536 interim Phase 1 dose expansion data to be presented in 2Q 2020 with more mature data expected in 2H 2020

Company to present preclinical data on ADCs created with the Dolasynthen and Immunosynthen platforms at the American Association for Cancer Research (AACR) Annual Meeting

CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2019.

We are excited to present updated data from our ongoing dose escalation study in heavily pre-treated and biomarker unselected patients at the upcoming SGO 2020 Annual Meeting on Womens Cancer. We plan to demonstrate that, at doses up to 43 mg/m2, XMT-1536 is well tolerated without the severe neutropenia, neuropathy or ocular toxicities typically observed with other ADC platforms, said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. Additionally, we continue to execute on our proof-of-concept expansion cohorts in ovarian and non-small cell lung cancer for XMT-1536 and are on track for additional data disclosures throughout the year. These data readouts will be important milestones as we chart a fast-to-market path to registration in ovarian cancer.

Recent Highlights and Updates

Clinical Programs

Discovery & Platform Progress

Upcoming First Quarter 2020 Events

2019 Financial Results

Cash, cash equivalents and marketable securities as of December 31, 2019, were $99.8 million, compared to $70.1 million as of December 31, 2018. In addition, the Company has the option to draw additional funds of up to $15.0 million through the existing debt financing agreement with Silicon Valley Bank. The Company expects that its current cash, cash equivalents and marketable securities will enable it to fund its operating plan through important milestones, including the XMT-1536 Phase 1 clinical study and the planned dose escalation study for XMT-1592.

Fourth Quarter 2019

Full Year 2019

Conference Call DetailsMersana Therapeutics will host a conference call and webcast today at 8:00 a.m. ET to report financial results for the fourth quarter and year-end of 2019 and provide certain business updates. To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 4849085. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at http://www.mersana.com.

About Mersana TherapeuticsMersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersanas lead product candidate, XMT-1536, is in a Phase 1 proof-of-concept clinical trial in patients with tumors likely to express NaPi2b, including ovarian cancer and NSCLC adenocarcinoma. Mersanas second product candidate targeting NaPi2b-expressing tumors, XMT-1592, is an ADC created using Mersanas customizable and homogenous Dolasynthen platform. The Companys early stage programs include a B7-H4 targeting ADC, as well as a STING agonist ADC developed using the Companys Immunosynthen platform. In addition, multiple partners are using Mersanas Dolaflexin platform to advance their ADC pipelines.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on managements beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Companys business strategy and the design, progression and timing of its clinical trials. Forward-looking statements generally can be identified by terms such as anticipates, believes, could, seeks, estimates, intends, may, plans, potential, predicts, projects, should, will, would or similar expressions and the negatives of those terms. Forward-looking statements represent managements beliefs and assumptions only as of the date of this press release. The Companys operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Companys results of operations and whether these forward-looking statements prove to be correct include, among other things, that preclinical testing may not be predictive of the results or success of ongoing or later preclinical or clinical trials, that the development and testing of the Companys product candidates and new platforms will take longer and/or cost more than planned and that the identification of new product candidates will take longer than planned, as well as those listed in the Companys Annual Report on Form 10-K filed on February 28, 2020, with the Securities and Exchange Commission (SEC) and subsequent SEC filings. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Mersana Therapeutics, Inc.Selected Condensed Consolidated Balance Sheet Data(in thousands)(unaudited)

Mersana Therapeutics, Inc.Condensed Consolidated Statement of Operations(in thousands, except share and per share data)(unaudited)

Contact:

Investor & Media ContactSarah Carmody, 617-844-8577scarmody@mersana.com

Read the original here:
Mersana Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Updates - BioSpace

Read More...

Indiana Regenerative Medicine Institute Offers Innovative Approaches in Regenerative Medicine, Hormone Replacement and Pain Management – Zionsville…

February 29th, 2020 7:48 am

February 2020

Are you looking for a health care provider who offers innovative alternatives and a customized approach to your health issues? Indiana Regenerative Medicine Institute (IRMI) believes in offering specialized alternatives to health care. Its medical team, headed by Doctor of Chiropractic Preston Peachee, utilizes the latest developments in regenerative medicine, hormone replacement and pain management.

Dr. Peachee is a native of Jasper, Indiana. He graduatedfrom Logan College of Chiropractic and has been in practice since 2003. Hisareas of specialty include patients with chronic and severe back, neck andjoint pain as well as other complex neurological conditions.

Dr. Peachee has earned a reputation as an innovative thinkeras well as a compassionate practitioner who brings his wide expertise andexperience to the Greater Indianapolis area. His ability to help those in needof regenerative medicine, neuropathy pain relief, low testosterone or otherphysical ailments, such as back pain or fibromyalgia, makes him not only uniquebut highly sought-after.

A key member of the IRMI team is Leann Emery, FNP. Emery isa family nurse practitioner with more than 20 years of experience in hormonereplacement and alternative pain management. Emery provides optimal patientcare through personal consultations and assessments to identify her patientsspecific health needs. She was rated in the top 10% of providers in the U.S.with patient satisfaction.

Regenerative medicine is making huge leaps in our understanding of the human body, and it is offering real, possible treatments that would have seemed like science fiction a few short years ago, according to IRMI. Most patients we see have tried other more traditional treatments and have either not gotten any better or have gotten even worse. Unfortunately, a lot of people we see depend on multiple medications per day to try and function but still are not happy with how they feel or how they live their lives. It is unfortunately the nature of deteriorating and degenerative joints, they will get worse with time, and generally the pain increases as well.

Depending on the injury, Dr. Peachee will often combinelaser therapy with the regenerative medicine protocols to improve the outcomesand try and speed the recovery process.

We offer mesenchymal stem cell therapy, Dr. Peachee said. With the combination of laser therapy, mesenchymal stem cell therapy is incredibly effective for rotator cuff problems and treating knee pain. Eighty percent of our stem patients are dealing with knee pain or Osteoarthritis. Osteoarthritis-or O.A. of the knee- is a huge problem for a lot of people, and we get great results from these therapies. Most people can even avoidknee surgery.

Dr. Peachee recently introduced hormone treatments for low testosterone. Family Nurse Practitioner Leann Emery has been doing [hormone] treatments for 20 years, and that area of medicine became a natural fit for IRMI.

I have several patients who were seeking this type ofcaremany who are police officers and firefighterswho couldnt find thetherapy and individualized care and attention that they needed.

Dr. Peachee explained that low T treatments help patients with unique and even complicated cases of Erectile Dysfunction (E.D.). Most people seek us out for treatment because they are tired, worn out, stressed out and just simply lack the energy they used to have.

We are able to fill a niche with patients who hadcomplicated cases that were not responding well with their primary careproviders or other places, Dr. Peachee shared. We have a patient who hasstruggled for a long time with fertility issues but has done very well [withtreatments], and we just got good news that he and his wife are expecting aftertrying for a really long time. So, he is really enthused about that.

The typical candidates for low T treatments, according toDr. Peachee, are men who feel worn out, are lethargic and have lost theirzest for life.

Our patients dont have the same pep that they had 10 or20 years ago, Dr. Peachee stated. They struggle getting up in the morning andmight be struggling in the afternoon after having six cups of coffee or threeRed Bulls just to get through the day. We have a lot of people that want to getback into the gym and get the maximum benefit of their workouts. We can helpthem improve their overall health and energy so that they can enjoyrecreational activities like working out or practice with the Little Leaguewith their kids. Many times we hear from spouses, friends and family how muchbetter they feel and that they seem happier and get more out of life again.

It goes without saying that proper hormonal balance canimprove a patients personal relationships as well and improve the overallmental health of a patient by reducing stress, anxiety and depression oftencaused by symptoms related to low testosterone levels.

We focus on injectable [low T] treatments because we canmodify the dosage and give more frequent doses to keep our patients at a levelthats going to give them the maximum benefit and improvement for theirconditions, Dr. Peachee explained.

With the modern changes in medicine over the last 20 and 50years, were helping people to live a lot longer and adding 20 to 30 years totheir lives, but we have not given them an improved quality of life as theyage. By working with their hormones and getting them in balance, their qualityof life becomes way better, and were seeing a positive improvement for manypeople with these treatments.

Patients suffering from severe disc injuries, such a bulgingor herniated disc or discs, or who suffer from degenerative disc disease mayhave undergone treatment from chiropractors or have seen physical therapistsbefore coming to Indiana Regenerative Medicine Institute.

Our typical patient who comes in for this type of treatmenthas seen other therapists or chiropractors but hasnt found lasting relief,Dr. Peachee said. Many of our patients want to get off the rollercoaster ofopioids and pain medications. They are looking for a solution without narcoticsand risk of addiction or other possible negative side effects of narcoticsand/or surgery. We are generally able to alleviate the pain in 90% of patientsand are able to keep them from having surgery or from taking addictivemedications.

Laser therapy allows Dr. Peachee to work on the damaged tissue so that it can heal, and the method reduces inflammation and swelling in a way that traditional treatments cannot.

Its an innovative new therapy within the last decade thatallows us to do some amazing things, Dr. Peachee stated. We perform ourprocedures in our office and have several different devices for the specificneeds and issues of our patients. For instance, we have a unique device forpeople with knee pain that can help the majority of our patients walk betterand live more pain-free. We get a phenomenal outcome with this procedure.

One of the other major differentiators that sets IndianaRegenerative Medicine Institute apart from other offices and clinics is thatthey are advocates for their patients, especially when it comes to dealing withtheir patients insurance providers.

A lot of our low T patients are able to get their insurancecarriers to cover the services so that it doesnt cost them as much out ofpocket for the care they seek, Dr. Peachee said. Weve partnered with abilling company that has helped us to be able to navigate the craziness of ourmodern insurance companies, and by doing so, were able to keep the cost downfor a lot of patients. Not every insurance plan will cover this type of care,but a lot of them will. When its possible and ethical, we do whatever we canto benefit our patients to help keep the cost low. I have spent a lot of freetime writing letters on behalf of our patients. We go above and beyond with ourservice and care of our patients.

The Indiana Regenerative Medicine Institute team will make housecalls or come to a patients place of work when the situation calls for thatlevel of care.

We will go and draw blood for blood work, bring medications and even do exams in some situations, Dr. Peachee said. As I mentioned before, we see a lot of police officers and firemen all over the statefrom Mishawaka to South Bend and all over Indiana. We go once a month to see these patients at their departments and stations so that we see them all in one day versus making 10 to 15 guys drive hours to come in to see us. Its a service we can offer because we are a small clinic and we are focused on that one-on-one patient attention and relationship building. We have great relationships with our patients, and thats something that we work very hard at.

Building trust and transparency is crucial to the success ofhis practice, Dr. Peachee emphasized. The trust that we build with ourpatients is crucial to not only the success of the practice but to thepatients outcomes. And not just with hormone therapy but also with ournonsurgical spinal decompression patients. These are patients with significant discinjuries, and we need them to tell us everything we need to know so we can givemore accurate and complete care for a better outcome.

I would say to anybody if you have any doubts or reservations to take some of the burden and some of the anxiety out of the equation and schedule an initial consultationabsolutely free of charge, Dr. Peachee encouraged.

Dont put off living your best life any longer. Visit Indiana Regenerative Medicine Institutes website at indianaregen.com or call (317) 653-4503 for more information about its services and specialized treatments and schedule your free consultationtoday!

Writer:

Janelle Morrison

Photography:

Laura Arick and submitted

Read more:
Indiana Regenerative Medicine Institute Offers Innovative Approaches in Regenerative Medicine, Hormone Replacement and Pain Management - Zionsville...

Read More...

Common sources of shoulder pain and how to treat it – Summit Daily News

February 29th, 2020 7:47 am

Editors Note: Sponsored content brought to you by Panorama Summit Orthopedics

Shoulder pain can range from temporary to long-lasting, from motion-related to constant, but one of the most disruptive symptoms of any shoulder injury is its effect on sleep.

When you dont sleep, everything in life becomes harder, said Dr. Aaron Black, a shoulder, knee and trauma specialist at Panorama Summit Orthopedics.

Some of the most common sources of shoulder pain include rotator cuff injuries and arthritis. In Summit County, its common to see patients who develop shoulder arthritis as a result of previous injuries to the shoulder, such as a shoulder dislocation earlier in life, Dr. Black said.

A specific diagnosis and treatment plan can result in years or perhaps a lifetime of pain relief and increased mobility in this important joint. Its Dr. Blacks mission to make sure hes helping patients not only eliminate shoulder pain and weakness, but also get back to consistently healthy and restful sleep.

Primary arthritis vs. rotator cuff arthropathy

The two broad categories of arthritis most commonly seen in Summit County are primary arthritis and rotator cuff arthropathy, or secondary arthritis. Primary arthritis has no specifically known cause and is usually related to age, sex and genes, according to the Arthritis Foundation. Rotator cuff arthropathy happens after a large, long-standing rotator cuff tendon tear that no longer holds the head of the humerus in the socket, causing it to move upward and damage the surface of the bones, according to the American Academy of Orthopaedic Surgeons.

Shoulder arthritis is experienced as achy pain and stiffness around the shoulder that often feels worse in the morning, Dr. Black said. Rotator cuff arthropathy is usually associated with stiffness and weakness.

Nonoperative arthritis treatment

Nonoperative shoulder arthritis treatment includes physical therapy and injection therapies.

As with any arthritic joint, the more you use it, the less stiff it is and the less pain you have, Dr. Black said.

PT can help improve range of motion in the shoulder, while icing the shoulder two or three times a day can reduce inflammation and ease pain.

Dr. Blacks injection therapy options include cortisone and biologic agents, such as platelet-rich plasma (PRP), all of which act primarily as anti-inflammatories.

No biologic injection therapies contain stem cells for tendons or cartilage, despite advertisements to the contrary, and thus do not regrow cartilage or tendons, he said.

Cortisone injections can offer pain relief for three to six months, while PRP tends to last a bit longer, Dr. Black said. The procedures are performed in the office under ultrasound guidance.

Shoulder joint replacement (arthroplasty)

If shoulder arthritis is severe, its less likely that the nonoperative options will get the job done. The next option for these patients would be shoulder joint replacement surgery.

Dr. Black said there are two types of shoulder replacements: anatomic total shoulder replacement and reverse total shoulder replacement. There are roughly 53,000 of these surgeries performed each year in the United States, according to the American Academy of Orthopaedic Surgeons.

Both procedures have differing benefits. Dr. Black said that anatomic replacements can be done on patients of any age, but those who have it at a younger age might require another surgery later in life. The procedure works well for getting patients back to their normal activities.

Reverse replacements are extremely reliable for reducing or eliminating pain, but less reliable for getting full range of motion back, he said.

I do all of my shoulder replacements with custom 3D modeling and patient-specific guides made to ensure the components are in exact right position, Dr. Black said.

Dr. Black stresses that all joint replacements are elective surgeries.

I will never tell a patient they have to have a joint replacement, he said. This is symptom-based when you say its time, its something Ill say you should have. I want all of my patients to be informed about the options.

Shoulder joint replacement recovery includes about six weeks in a sling, and in three to four months most patients are back to regular activity with continued improvement from there.

Rotator cuff injuries

Another common local shoulder affliction is to the rotator cuff, which is the combination of muscles and tendons that keep your arm bone centered in your shoulder socket to provide shoulder motion and stability. Dr. Black said these injuries can happen during a fall when the arm is thrown away from the body, but sometimes rotator cuff injuries are chronic and happen over time.

Some people even have large tears to the rotator cuff without ever feeling any symptoms.

The good news is that there are a lot of treatment options, from physical therapy and injections to repair or reconstruction surgery.

Read the original post:
Common sources of shoulder pain and how to treat it - Summit Daily News

Read More...

Rheum Round-up: Heres What Rheumatologists and Patients Value in Rheumatoid Arthritis Treatment, Plus How Kidney Injury Affects Surgery Complications…

February 29th, 2020 7:47 am

Here are the top stories recently covered by DocWire News in the Rheumatology section. In this edition, read about what rheumatologists and patients believe is the most important in rheumatoid arthritis treatment, the effects of acute kidney injury on hip arthroplasty complications, the best technique for traumatic finger amputation, and seasonal effects on symptoms including fatigue on primary Sjgrens syndrome.

A new study assessed the preferences of patients and rheumatologists regarding treatment attributes for rheumatoid arthritis (RA) as well as their feelings regarding shared decision-making. Three steps were taken: literature review, RA patient focus group discussion, and rheumatologist focus group discussion. A total of 90 rheumatologists (mean years of experience, 18.1 years; 52.2% were female; average RA patients per week, 24.4) and 137 RA patients (mean age, 47.5 years; 84.0% were female; mean time since RA diagnosis, 14.2 years; mean time in treatment, 13.2 years) were included in the study. Although the top three attributes were the same between patients and rheumatologists, the order in which they were ranked differed, with patients placing the highest value on time with optimal quality of life (QoL) followed by mode of administration and time to onset of treatment action, compared to rheumatologists, who ranked the top three attributes as mode of administration, time with optimal QoL, and time to onset of treatment action.

A new study highlighted the effects of acute kidney injury (AKI) on complication risk in total hip arthroplasty (THA) patients. The study authors concluded that AKI significantly increases postoperative complication risks, including mortality, and recommend that increased focus be placed on reducing AKI risk. A total of 4.1 million primary THAs were performed during the study period, of which 61,077 (1.5%) included AKI during hospitalization. Unadjusted analyses unearthed a correlation between AKI and higher rate of complications and healthcare utilization. When adjusting for age, gender, race, income, underlying diagnosis, medical comorbidity, and insurance payer, AKI presenting in primary THA was significantly increased risks for implant infection, transfusion, revision, death, total hospital discharges above the median, discharge to a rehabilitation facility, and hospital length of stay longer than three days.

A new study examined whether season has an impact on symptoms of fatigue, pain, and dryness in primary Sjgrens syndrome. The present study evaluated patient data from the French nationwide multicenter pSS cohort Assessment of Systemic Signs and Evolution in Sjgrens Syndrome (ASSESS) (n=395). ASSESS was created in 2006 and houses five-year prospective follow-up data as well as data from three randomized, placebo-controlled trials of infliximab, rituximab, and hydroxychloroquine. In each study, visits included data collection on visual analog scale (VAS) scores for pain, fatigue, and dryness. Data were assessed by the day, month of the year, and season. VASs did not largely differ among the seasonal groups. The EULAR Sjgrens Syndrome Patient Reported Index scores did not significantly differ by season: spring, 57.7; summer, 59.5; fall, 55.9; and winter, 57.2.

A study questioned which is the best strategy to employ in traumatic finger amputations and concluded that the target technique will depend on the patient. The researchers reviewed data from a retrospective cohort study who underwent revision amputation or replantation at 19 U.S.- and Asia-based centers between Aug. 1, 2016, and April 12, 2018. The present analysis included data on 185 patients. The primary outcomes were hand strength, dexterity, hand-related quality of life, and pain, and the study authors employed a tree-based statistical learning method to obtain clinical decision rules for traumatic finger amputation treatment. Implementation of the tree-based statistical learning estimates found that different strategies were associated with different outcomes. Maximal hand dexterity or minimal patient-reported pain was obtained through replantation. Maximal hand strength was obtained through revision amputation in the case of a single-finger amputation; in all other cases, replantation was the best approach. Maximal patient-reported quality of life was obtained through revision amputation in patients with dominant hand injuries, and replantation was favorable in the case of nondominant hand injuries.

Read more here:
Rheum Round-up: Heres What Rheumatologists and Patients Value in Rheumatoid Arthritis Treatment, Plus How Kidney Injury Affects Surgery Complications...

Read More...

YOUR HEALTH: Knee relief can be found in the womb – WQAD.com

February 29th, 2020 7:47 am

CHICAGO About 54 million Americans suffer from the aches and pains of arthritis.

Treatments range from pain medications to injections to surgery.

None of it seemed to work for 77-year-old Marty Ciesielczyk.

And it jeopardized something he loved: jogging.

"For me, it's just enjoyable, and if you're not a runner, then you would have no idea what I'm talking about."

But Marty's active lifestyle was in jeopardy when knee pain took over.

"When you got to lay on the floor to get dressed, it's tough."

It happens when there's a loss of cartilage in the joint.

"It's like a tire, and as you slowly lose rubber on the tire, it wears away," explained Dr. Adam Yanke, a surgeon with Midwest Orthopaedics at Rush University.

"You might need to have the tire replaced at some point."

Marty's arthritis was too advanced for a scope procedure but not bad enough for a joint replacement.

So he enrolled in a study testing whether amniotic fluid, which surrounds a growing baby in the uterus, could help his pain.

"Amniotic products come from patients that are having healthy, elective C-sections, and they choose to donate these products at the time of the delivery," said Dr. Yanke.

It's thought to increase tissue healing and lower inflammation.

Doctor-diagnosed arthritisis more common in womenthan in men. Arthritis and other joint disorders are among the five most costly conditions among adults 18 and older.

Your bone marrow makes mesenchymal stem cells, or MSCs. They are known to grow into new tissues, including cartilage.

By gathering these cells and injecting them into the knee joint, the hope is that they will give growth to new cartilage and reduce inflammation.

Marty received a placebo during the study, but then chose to have the amniotic fluid when the study ended.

"I mean I didn't care if it was Pixie dust, as long as my knee was going to feel better."

He went from not being able to get dressed to jogging about a week after having the injection.

"This morning, I ran three, three miles, and I had no problem at all."

Amniotic fluid is also being used to treat ulcers in the eye.

Rush University will be enrolling patients for a larger follow-up study on amniotic fluid for joint pain in the future.

Clinical trialsare still going on and most studies are still early.

A review published in 2016 in BMC Musculoskeletal Disorders concluded that MSC-based therapies offer an "exciting possibility" for treatment, but further studies need to be done on how they can best be used and how well they work.

They are also known to be very expensive.

If this story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Jim Mertens atjim.mertens@wqad.comor Marjorie Bekaert Thomas atmthomas@ivanhoe.com.

Excerpt from:
YOUR HEALTH: Knee relief can be found in the womb - WQAD.com

Read More...

What is gout? How to know if you have it and recommended treatment – Business Insider

February 29th, 2020 7:47 am

captionGout is associated with frequent joint pain.sourceljubaphoto/Getty Images

Gout is an intensely painful form of arthritis that affects over 8 million Americans. As our diets change to include more processed foods, and with the increase in popularity of high protein diets, gout is on the rise, especially for older men. Heres what you need to know about the causes, symptoms, and treatment for gout.

Gout causes your joints to swell up and become extremely painful. Its the most common type of inflammatory arthritis and is caused by a buildup of uric acid, a waste product that is produced when your body breaks down a chemical called purine in certain foods.

Gout is caused by a condition called hyperuricemia, which means there is an excess of uric acid in the blood. Uric acid is normally diluted in your blood and leaves the body through your urine, but when you have too much uric acid in your blood, the acid can crystallize and build up in your joints, causing gout symptoms.

Foods with high concentrations of purines include red meat, alcohol, and fruit juices even if they are naturally sweetened. In addition, seafood like sardines, tuna, and shellfish also contain purine and should be eaten only in moderate amounts. Read our article on the best diets for gout for more information on what you should be eating and avoiding.

Western-style dietary patterns seem to increase the risk of gout, says Hyon K. Choi, MD, a professor of Medicine at Harvard Medical School. A typical Western diet includes large amounts of processed carbohydrates like high fructose corn syrup, red meat, and saturated fats.

Obesity may also be a risk factor: A study, published in Arthritis Care & Research in 2012, found that people who are obese are around twice as likely to suffer from gout compared with people whose body mass index falls in the normal range.

Other risk factors include sex and age. Men are more likely to develop gout, in general, and women are at greater risk after menopause.

Some people may only have gout attacks periods of acute pain and swelling in joints once or twice in their lifetime, while others with chronic gout may have frequent attacks, several times a year, that dont fully heal in between episodes.

Some of the most common symptoms of gout are:

The symptoms of gout usually come and go, says Choi, although patients can have chronic joint pain if the gout is severe or longstanding.

When you have an acute attack of gout, your doctor will likely focus on treating your immediate symptoms first by prescribing non-steroidal anti-inflammatory drugs to help bring down the pain and swelling. For patients who get frequent flares of gout, long-term treatment with a medication that lowers uric acid levels, such as allopurinol, is recommended, Choi says.

However, while symptoms of gout can be controlled with medications, it is also important to implement lifestyle changes, Choi says, adding that a good place to start is adopting a healthy diet and exercise.

Left untreated, gout can increase your risk of developing heart disease, type 2 diabetes, and chronic kidney disease.

Over the long term, losing weight may be an important step to treat gout, as being overweight increases your chances of developing gout. However, you should avoid extreme dieting, as losing weight too quickly can actually trigger gout attacks.

Avoiding high purine foods can help lower uric acid in your body, and consuming certain foods like vitamin C and coffee may help treat gout, according to some research.

Choi says that overall, the Mediterranean and DASH (Dietary Approaches to Stop Hypertension) diets seem to be beneficial for patients with gout. This means adding more whole grains, vegetables and fruits, and legumes to your diet and eating less meat. For more information about what to eat for each of these diets, check out our articles about the Mediterranean diet and the DASH diet.

Gout can be painful in the short term and can lead to serious illnesses in the long term, but there are treatments available to lower your risk. The best place to start is to talk to your doctor about diet and lifestyle changes you can make to improve your health.

More here:
What is gout? How to know if you have it and recommended treatment - Business Insider

Read More...

Page 681«..1020..680681682683..690700..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick